Key result
Anticoagulation for valvular heart disease linked to ~102% higher major hemorrhage risk versus atrial fibrillation.
Why the study?
Little is known about the characteristics, management, and outcomes of patients receiving oral anticoagulation for valvular heart disease in community-based practice compared to those anticoagulated for atrial fibrillation.
Does oral anticoagulation for valvular heart disease have different safety and efficacy outcomes compared to anticoagulation for atrial fibrillation in community-based practice?
Cohort (n=4,453)
Yes
Does oral anticoagulation for valvular heart disease have different safety and efficacy outcomes compared to anticoagulation for atrial fibrillation in community-based practice?
Answers are grounded in this paper and cite their sources.
In community-based practice, patients receiving warfarin for valvular heart disease experience similar anticoagulation control but a twofold higher risk of major hemorrhage compared to those treated for atrial fibrillation.
Little is known about patients who receive oral anticoagulation for valvular heart disease (VHD) in community-based practice. It was this study's objective to describe the characteristics, management, and outcomes of patients anticoagulated for VHD, compared to patients anticoagulated for atrial fibrillation (AF). We used a nationally-representative cohort of community-based anticoagulation care in the United States. Data collected included indications for therapy, demographics, selected comorbid conditions, international normalised ratio (INR) target ranges, INR control, and clinical outcomes. We identified 1,057 patients anticoagulated for VHD (15.6% of the overall cohort) and 3,396 patients anticoagulated for AF (50.2%). INR variability was similar between the two groups (0.64 vs. 0.69, p = 0.80). Among patients with aortic VHD, for whom a standard (2-3) target INR range is recommended, 461 (84%) had a high target range (2.5-3.5), while 95 (16%) had a standard target range. VHD patients had a higher rate of major haemorrhage compared to AF patients (3.57 vs. 1.78 events per 100 patient-years, incidence rate ratio 2.02, 95% CI 1.33 - 3.06). The rate of stroke/systemic embolus was similar between groups (0.67 vs. 0.97 events per 100 patient-years, incidence rate ratio 0.71, 95% CI 0.32 - 1.57). In our community-based study, approximately 15.6% of patients receiving warfarin were anticoagulated for VHD. VHD patients achieved similar anticoagulation control to patients with AF, as measured by INR variability. Nevertheless, the rate of major haemorrhage was elevated among VHD patients compared to AF patients; this finding requires further investigation.
No takes yet. Share an insight, caveat, or question.
A 2009 study conducted a cohort in Valvular heart disease and atrial fibrillation (n=4,453). Anticoagulation for valvular heart disease vs. Anticoagulation for atrial fibrillation was evaluated on Major haemorrhage (IRR 2.02, 95% CI 1.33 - 3.06). Patients anticoagulated for valvular heart disease had a higher rate of major haemorrhage compared to those with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: